Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Measuring Quality of Care for Prostate Cancer
- Prostate cancer is the most common solid malignancy diagnosed in American men. There is a need for valid measures for assessing quality of care for prostate cancer, and there is a need to understand how variations in quality of care affect treatment outcomes. This report summarizes the work "Prostate Cancer...
- White papers
- Advanced Radiation Therapy Treatments at the Rajiv Gandhi Cancer Cancer Institute, New Delhi
- One of the greatest challenges of using radiation therapy for the treatment of cancer is to deliver the highest possible dose to the malignant tissue and, at the same time, ensure that normal tissues closest to the tumor receive the lowest possible dose. Medical centers with radiation therapy departments face...
- Case studies 2005-04-25
- How Complete and Accurate Are Cancer Registrations Notified by the National Health Service Central Register for England and Wales?
- A voluntary system of central registration of cancers has been in operation throughout England and Wales since 1971. Regional cancer registries ascertain details of cancer diagnoses from hospitals and other sources in their areas and forward these to the National Cancer Intelligence Centre formerly the National Cancer Registration Bureau, which...
- White papers 2001-01-14
- NeoGenomics Inc: The Wall Street Analyst Forum Presentation Transcript
- Earnings Call Excerpt NeoGenomics Inc. NGNM Wall Street Analyst Forum Presentation November 28, 2007 10:30 am ET Executives Robert Gasparini – President & Chief Science Officer Steven Jones - Chief Financial Officer Presentation Moderator Good morning ladies and gentlemen. I’d like to go ahead and introduce the next company...
- Earnings calls 2007-11-28
- Myriad Genetics Inc. F2Q09 (Qtr End 12/31/08) Earnings Call Transcript
- Question-and-Answer Session Operator Operator Instructions Our first question comes from the line of Charles Duncan of JMP Securities. Please proceed with your question. Charles Duncan - JMP Securities Hi, guys. Good morning and congratulations on a very good quarter. My question is regarding perhaps the breadth of potential...
- Earnings calls 2009-02-03
- Cancer drug audit set for late start
- Eight months after promising to audit the demand for cancer and other drugs that the NHS declines to fund, pilot projects to achieve that have yet to be launched, the Department of Health said yesterday.The pilot schemes should finally begin "later this year", a spokesman said as the Rarer...
- External links 2009-08-13
- Gen-Probe Wages Bidding War For Diagnostics Crown
- Diagnostic tests traditionally haven't gotten a huge amount of respect within the drug industry. Until recently, at least, most diagnostics were low-margin, almost commodity products that couldn't command the high prices -- much less the repeat business -- that drugs themselves could. That's started to change with...
- Blog posts 2008-06-04
- Dissecting Merck's "Gardasil for Boys" FDA Application
- Merck has filed an application with the FDA for the use of the HPV vaccine Gardasil in boys. The move was predicted by BNET on Nov. 14. It will likely spur two debates, one over the safety of the vaccine and another over whether Gardasil is actually cost-effective enough to...
- Blog posts 2009-01-06
- Amylin Insists Byetta Doesn't Cause Cancer; Wall Street Doesn't Seem So Sure
- Amylin CEO Daniel Bradbury may be wishing that Novo Nordisk's failed competitor to its diabetes drug Byetta had actually been approved by the FDA. Had Novo's liraglutide passed muster, no one would have gotten the jitters over whether Byetta gives you cancer or not. At Amylin's conference...
- Blog posts 2009-04-21
- Sanofi's Lantus Cancer Scare Shows How Enormous Power Lies With Few Experts
- The cancer scare over Sanofi-Aventis' Lantus shows just how much power over a company's drug sales -- and its stock -- are now concentrated in the hands of a tiny number of experts. Sanofi CEO Chris Viehbacher came out of his corner swinging Monday, saying an article in Study of...
- Blog posts 2009-06-29
- UPDATED: Sanofi's Lantus Cancer Scare Triggered by Doc Backed by Amylin and Lilly
- The editors of medical journal backed off from a study they published suggesting Sanofi-Aventis' diabetes drug Lantus was linked to cancer. At the same time, it emerged that the doctor who warned of an "earthquake" on Lantus has done work endorsed or sponsored by Amylin and Eli Lilly, marketers of...
- Blog posts 2009-07-01
- Cynicism Winning Debate Over Sanofi's Lantus and Cancer
- In the flap over whether Sanofi-Aventis' Lantus diabetes drug has an association with cancer, cynicism seems to be winning. Sanofi's stock see graph seems not to have recovered from reports that Lantus was linked to cancer, even though Sanofi obtained an approval for a new heart drug, Multaq. Meanwhile, Sanofi's...
- Blog posts 2009-07-07
- Latest Gardasil-for-Boys Scare Tactic: Penile Cancer
- Back in November, BNET suggested we were about to see a media campaign full of scary stuff -- anal cancer, anyone? -- for which the prevention is Merck's HPV vaccine, Gardasil. This week, it arrived. Spanish researchers found that 46.9 percent of all penile cancers are caused by HPV. by...
- Blog posts 2009-08-27
- Roche Developing a "Hedgehog Inhibitor" for Cancer
- Roche has a "hedgehog inhibitor" in Phase 2 of development, according to an investor presentation that accompanied its Q3 2009 results. Don't panic. This is not a substance intended to kill the spiny-but-adorable endangered species native to the hedgerows of Europe. Rather, it's a new therapy for basal cell carcinoma...
- Blog posts 2009-10-15
- Amgen's Denosumab Delay Not a Deal-Breaker; Cancer Remains the Big Question
- The FDA's complete response letter to Amgen regarding approval of denosumab for postmenopausal osteoporosis was an unpleasant surprise that could have been much worse, but the drug’s biggest test is yet to come when the agency reviews its bids in cancer. by Trista Morrison
- Blog posts 2009-10-19
- Has Genta's Energizer Bunny of Cancer Drugs Finally Run Out of Juice?
- The most surprising thing about last week's Phase III failure of beleaguered cancer drug Genasense was that Genta's stock plummeted. Seriously, who didn't see this one coming? by Trista Morrison
- Blog posts 2009-11-04
- ArQule Joins Forces with Daiichi Sankyo to Fight Cancer
- Eben Tessari submits: ArQule and Daiichi Sankyo announced that they have entered into two agreements that form the basis of a strategic relationship for the development and discovery of novel oncology therapeutics. One agreement covers the license of ARQ 197 and the other is an R&D agreement. ARQ...
- External links 2008-11-11
- Technical Advances in Colorectal Cancer Screening
- In the colon and rectum, the vast majority of cancers develop very slowly, approximately over a period of 10 to 15 years, from benign precursor lesions. These lesions, so-called polyps, can undergo malignant transformations based on the adenoma-carcinoma sequence. Therefore, the resection of polyps reduces colorectal cancer mortality by over...
- White papers 2005-10-01
- Increased Risk of Cancer Among Relatives of Patients With Lung Cancer in China
- Genetic factors were considered as one of the risk factors for lung cancer or other cancers. The aim of this paper was to determine whether a genetic predisposition accounts for such familial aggregation of cancer among relatives of lung cancer probands. A case-control study was conducted in 800 case families...
- White papers 2005-11-11
- What I Need to Know About Colon Polyps
- This paper discusses and provides information on Colon Polyps. A polyp is extra tissue that grows inside the body. Most polyps are not harmful. Symptoms may include constipation or diarrhea for more than a week or blood on your underwear, on toilet paper, or in your stool. Many polyps do...
- White papers 2003-04-01
- << Previous
- page 1 of 2
- Next >>
Content Types
Refining Tags
- Jim Edwards (7 results)
- Human Resources (6 results)
- Healthcare (6 results)
- Gender And Diversity (5 results)
- Management (5 results)
- Strategy (4 results)
- Finance (4 results)
- Investment (3 results)
- Seeking Alpha (3 results)
- Medicare (3 results)
- Marketing (3 results)
- BioMed Central (3 results)
- Patient (3 results)
- Colorectal Cancer (3 results)
Premier Vendor Content Whitepapers, webcasts & resources from our Power Center Sponsors
